Skip to main content
SpringerLink
Log in

Vericiguat cost effective for treatment of chronic HF with reduced ejection fraction following worsening HF event

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA.

Reference

  • Alsumali A, et al. Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective. PharmacoEconomics : 8 Oct 2021. Available from: URL: https://doi.org/10.1007/s40273-021-01091-w

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vericiguat cost effective for treatment of chronic HF with reduced ejection fraction following worsening HF event. PharmacoEcon Outcomes News 889, 30 (2021). https://doi.org/10.1007/s40274-021-08118-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-08118-1

Search

Navigation